Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...

Results provide a mechanistic explanation of why early loss of p53 signaling is frequently observed in UC-associated ...

The findings offer a promising drug target to prevent progression to colon cancer by targeting abnormal cells early on.

New research highlights a pivotal role for the p53 gene in ulcerative colitis progression, offering a potential therapeutic ...

US pharma major Eli Lilly has released results from two, multi-year, Phase III studies that showed patients treated with ...

A team of researchers led by Kimberly Hartl, a graduate student at the Berlin Institute for Medical Systems Biology of the ...

Researchers in the lab of Michael Sigal at the Max Delbrück Center and Charité – Universitätsmedizin Berlin have elucidated ...

Abdominal pain, diarrhea, and debilitating fatigue define the daily lives of millions of people worldwide who suffer from ...

DRB1*01:03 allele was significantly associated with increased severity of ulcerative colitis, including higher rates of ...

Eli Lilly announced that mirikizumab achieved long-term remission in Phase 3 IBD studies, showing promise for ulcerative ...

New research from Denmark sheds light on why ulcerative colitis affects patients differently, moving us closer to ...

ALTB-268 demonstrated its anti-inflammatory effect in an acute colitis hPSGL-1 mouse model.The data confirmed that ALTB-268 acts as an immune ...